Clinical Trials Logo
  1. Home
  2. Neuroendocrine Carcinoma
  3. NCT02236910

An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours

Neuroendocrine Carcinoma Clinical Trial

Official title:
An Open Label Phase II, Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours

Clinical Trial Summary

Lu-DOTA-TATE (Lutetium-177 octreotate) is a radiopharmaceutical that has been reported as being effective in controlling symptoms and increase quality of life; induce stable disease and extend progression free survival; induce a (good) partial remission and induce a complete remission in patients with a somatostatin receptor positive tumour. The purpose of this study is to assess the efficacy of Lu-DOTA-TATE by measuring progression free survival and overall survival. This study will also asses the safety of Lu-DOTA-TATE, and the quality of life of the patients treated with Lu-DOTA-TATE.

Clinical Trial Description

Neuroendocrine (NET) tumours have secretory and metabolic pathways not typically found in other cancers that can be utilized for molecular imaging and therapeutic targeting. The most important is somatostatin. Somatostatin receptors are useful tools in the diagnosis and treatment of NET tumours because the somatostatin analogue octreotate can be radiolabeled with lutetium-177 for imaging and therapy. In selected populations of patients, radioisotope therapy in expert hands has been shown to be a safe and effective palliative therapy with stable disease, progression free survival benefit, symptom control and improvements in quality of life. Lutetium-177 (DOTA0, Tyr3) octreotate has been used in a significant number of clinical studies shown to be safe and effective as a therapeutic agent in patients with NET tumours. The investigators intend to further confirm these benefits with lutetium-177 octreotate, which could form the basis for a national registry study leading to registration of this therapeutic intervention. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02236910
Study type Interventional
Source Lawson Health Research Institute
Contact
Status Active, not recruiting
Phase Phase 2
Start date July 2014
Completion date December 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT01642251 - Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT04069299 - Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
Recruiting NCT04464122 - Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Recruiting NCT04325425 - Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary Phase 2
Completed NCT03834701 - Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms N/A
Recruiting NCT03279614 - Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma Phase 2
Recruiting NCT05978284 - Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma Phase 1/Phase 2
Recruiting NCT05076786 - Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma Phase 2
Completed NCT00388063 - Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Phase 2
Withdrawn NCT03901378 - Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma Phase 2
Recruiting NCT02970786 - Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans Phase 1
Completed NCT00663429 - Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma Phase 2
Recruiting NCT05113355 - Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm Phase 2
Completed NCT03278405 - Avelumab in G3 NEC Phase 1/Phase 2
Active, not recruiting NCT03837977 - Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma Phase 2
Recruiting NCT06372626 - Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. Phase 1/Phase 2
Not yet recruiting NCT06333314 - Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI Phase 2
Active, not recruiting NCT02687958 - Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin Phase 2
Completed NCT01121939 - Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers Phase 2
Recruiting NCT03168607 - Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma Phase 2